Hemostemix Inc. (CVE:HEM – Get Free Report) fell 19.4% during trading on Wednesday . The stock traded as low as C$0.14 and last traded at C$0.15. 215,053 shares were traded during trading, a decline of 58% from the average session volume of 513,395 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The firm has a market capitalization of C$25.50 million, a PE ratio of -5.10 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company’s fifty day simple moving average is C$0.20 and its 200 day simple moving average is C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- 3 Small Caps With Big Return Potential
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- About the Markup Calculator
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
